Research: REGEN and COLLEAGUES,

Listed in Issue 228

Abstract

REGEN and COLLEAGUES, (1)Department of Psychiatry, Clinical Neurobiology, Charité - Campus Benjamin Franklin, Berlin, Germany. (2)Department of Psychiatry, Clinical Neurobiology, Charité - Campus Benjamin Franklin, Berlin, Germany. Electronic address: julian.hellmann@charite.de investigated a hypothetical link between retinoic acid (RA) signalling  and minocycline [a tetracycline antibiotic that fights bacteria in the body] for targeting prostate carcinoma (PCA).

Background

To elucidate a hypothetical link between retinoic acid (RA) signalling and minocycline [a tetracycline antibiotic that fights bacteria in the body] for targeting prostate carcinoma (PCA). RA signalling has been implicated in growth-inhibition of malignant PCA, and intracellular RA homeostasis has been investigated as a potential therapeutic target. Minocycline is a tetracycline antibiotic with pleiotropic actions in many tissues and reaches comparably high levels in human prostate tissue. Interestingly, minocycline exhibits the rare side effect of a pseudotumor cerebri, which is otherwise known to occur from vitamin A intoxication or in retinoid therapy. Therefore, we hypothesized minocycline to putatively interact with intracellular RA homeostasis in PCA.

Methodology

Using LN-CAP, DU-145, and PC-3 cell lines, effects of minocycline on microsomal RA metabolism and on cell growth were assessed in vitro.

Results

Minocycline was identified to potently inhibit cell growth, at concentrations within the range of tissue levels readily reached under standard therapeutic conditions. In vitro inhibition experiments revealed inhibition of RA breakdown, yet only at comparably high concentrations of minocycline. Using all trans-RA, RA metabolism inhibitor liarozole, and different retinoid receptor antagonists, the putative RA-dependent effects of minocycline were further evaluated and confirmed to be independent of RA signalling.

Conclusion

The authors’ findings add to the growing body of evidence for the many pleiotropic actions of minocycline. In view of the striking effects of minocycline on cell growth in PCA cell lines in vitro and its relatively safe side effect profile, the use of minocycline for targeting PCA should be timely clinically evaluated.

References

Regen F(1), Heuser I(1), Herzog I(1), Hellmann-Regen J(2). Striking growth-inhibitory effects of minocycline on human prostate cancer cell lines. Urology 83(2):509.e1-6. doi: 10.1016/j.urology.2013.10.029. Feb 2014. Epub 2013 Dec 19.

ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page